The Hidden War Behind the Pharmaceutical King's Succession: How a $36.5 Billion Order Tests the Global Supply Chain

Ⅰ. A historic shift

In 2025, the global pharmaceutical industrysaw a historic shift: Eli Lilly’s tirzepatide narrowlydethroned Novo Nordisk’s semaglutide as the new"King of Pharmaceuticals" with $36.5 billion in annual sales. Beyondclinical efficacy and marketing, this milestone hides a deeper battle—supply chains and API production. For industry professionals andinvestors, this succession underscores that in the competitive GLP-1 era,stable, scalable and cost-effective API supply capacity determines success.

II. Our Company: Standing Out with"Strong Production Capacity + Efficient Business Capabilities"

Amid this fierce competition for APIsupply, our company, as a core force in China’s peptideAPI industry, stands out as an indispensable partner for global pharmaceuticalcustomers. Leveraging our unique dual-core advantage—"strongproduction capacity of Guizhou production base + efficient businesscapabilities of Hong Kong company"—we perfectlyaddress the core demands of global clients: high purity (≥99.5%), stable output, and cost advantages that directly boost theirprofit margins. We also solve key pain points foreign customers face whensourcing from China, earning wide trust through proven results.

2.1 Guizhou Production Base: Core Carrierof Strong Production Capacity

Our core production base, Guizhou UtideBiotechnology Co., Ltd. in Zunyi, Guizhou, is a 20,000-square-meterGMP-compliant facility—one of the largest single-unitpeptide API production bases in Southwest China. Equipped with world-classcontinuous manufacturing technology (breaking traditional SPPS bottlenecks), itachieves an annual output of 500kg high-purity GLP-1 APIs (purity ≥99.5%), with a yield of over 95% (far exceeding the 85% industryaverage) and a 40% shorter production cycle. Covering the entire productionprocess and strict quality control, it stably meets both large-volume ordersfrom global giants and small-batch customization, with a product portfolioincluding semaglutide and retatrutide. A European diabetes drug client (ClientA) switched to us after facing unstable purity (97%-98.5%) and delayeddeliveries with two previous suppliers; our 100% on-time delivery andhigh-purity products increased their pass rate by 15% and eliminated orderlosses.

2.2 Hong Kong Company: Core Platform ofEfficient Business Capabilities

UTIDE BIOTECH (HK) CO., LIMITED, ourexclusive overseas business entity, serves as a reliable bridge between ourGuizhou base and global clients. Staffed by professionals proficient ininternational pharmaceutical norms, it provides one-stop cross-border services—demand communication, order management, document sorting,cross-border settlement, and logistics tracking. The team accurately transmitsclient needs to the Guizhou factory and feeds back real-time productionupdates, ensuring smooth cooperation and solving pain points likemiscommunication and inconsistent demand transmission.

2.3 Dual-Core Synergy: Solving theIndustry's "Impossible Trinity" Dilemma

Our dual-core synergy perfectly solves theglobal industry’s "impossible trinity"(Scale, Quality, Cost) and cross-border cooperation pain points. A NorthAmerican biopharmaceutical client (Client B) previously faced miscommunicationand unstable supply with Chinese suppliers; after cooperating with us, our HongKong team ensured accurate demand transmission, and our stable productioncapacity met their sudden order surge, boosting their annual profit by 20%.This irreplicable advantage makes us the preferred partner for global giantsbuilding resilient supply chains.

III. Product Hotspot Ignites Market Boom,Peptide API Demand Surges

The rivalry between Eli Lilly and NovoNordisk drives the GLP-1 market, fueled by explosive demand for weightmanagement and type 2 diabetes treatments. Semaglutide once dominated over 60%of the market by 2024, but tirzepatide’s superior dualmechanism reshaped the market in 2025. With the global GLP-1 market approaching$60 billion in 2025 (40% annual growth), peptide APIs—coreraw materials—are in unprecedented demand,restructuring the global supply pattern.

IV. Global Chemical ProductivityRestructuring: Peptide APIs Are Increasingly Sourced from China

Against surging global demand, globalpeptide API production capacity is accelerating its shift to China—an inevitable result of global chemical restructuring. Europe andthe US transfer high-energy-consuming pharmaceutical production overseas due tostrict environmental policies, high labor costs (3-5x China’s), and long capacity expansion cycles (2-3 years). In contrast,China’s complete industrial chain, low costs, policysupport, and advancing peptide technology make it the world’s core supply base.

V. The Boom of Domestic Peers: The RisingHeat of China's Peptide API Industry

Driven by global capacity transfer anddemand surge, outstanding domestic peers (Hybio Pharmaceutical, ZhejiangPeptites Biotech, CPC Scientific, AmbioPharm, Lunan Pharmaceutical) haveemerged, verifying China’s peptide industry potentialand setting benchmarks for our continuous optimization. Together, they driveindustry growth and attract global capital.

VI. The Future War: Beyond Capacity,Winning with Dual-Core Advantages

Post-2025 "King ofPharmaceuticals" succession, GLP-1 competition will go beyond capacity—technological iteration and green manufacturing will determinelong-term success. Our Guizhou factory leads in green production: its solventrecovery technology cuts consumption by 60%, and renewable energy use reducescosts and environmental impact, boosting global competitiveness.

For investors and global clients, ourdual-core advantages (high purity, stable capacity, efficient cross-borderservices) ensure stable returns and reduced procurement pain points. As GLP-1demand expands, we will play a more critical role in the global supply chain,creating greater value for clients and investors.

The 2025 "King ofPharmaceuticals" succession highlights that supply chain resilience equalsclinical innovation. With Guizhou Utide as our production core and UTIDEBIOTECH (HK) as our overseas window, we are emerging as a key force in global healthcare,offering high-quality products and professional services to global clients.